Article Text

AB0468 Possible effects of belimumab therapy on t- and b-cell phenotype in a cohort of patients with systemic lupus erythematosus
  1. S Piantoni1,
  2. F Regola1,
  3. M Scarsi2,
  4. F Dall'Ara1,
  5. L Andreoli1,
  6. A Tincani1,
  7. P Airò1
  1. 1Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia
  2. 2Internal Medicine Unit, Esine-Vallecamonica Hospital, Esine, Italy


Background B- and T-cell activation are one of the pathogenic mechanisms of systemic lupus erythematosus (SLE). After repeated antigenic stimulation, T-cells undergo different modifications, leading to the differentiation into effector memory T-cells (CCR7-CD45RA-) and highly experienced memory T-cells (CCR7-CD45RA+). Similarly, down-modulation of CD28 may lead to the expansion of the CD28neg T-cells, a subpopulation with peculiar effector activities (1).

Recent studies showed that memory CD4+ T-cells are increased in the peripheral blood of SLE patients, whereas contradictory data are reported on CD28 neg T-cells (2).

Peripheral transitional B-cells (38high24high) are immature B-cells transiting to secondary lymphoid organs, where their maturation into follicular or marginal zone B-cells is driven by a stimulating factor called BLyS. This population is expanded in patients with SLE (3). The anti-BLyS therapy agent belimumab is approved for treatment of SLE.

Objectives The aims of this study were to characterize B- and T-cell phenotype in a cohort of patients with SLE, according with disease activity, and to analyse their modifications therapy with belimumab.

Methods Phenotypic analysis of peripheral blood B and T lymphocytes was made by flow-cytometry. First, a cross-sectional study on 51 consecutive SLE patients (F/M: 48/51; median age: 35 years; anti-dsDNA: 16 UI/ml; C3: 79 mg/dl; C4: 10 mg/dl) was performed.

Second, 18 patients treated with belimumab were longitudinally followed.

Disease activity was evaluated by SLEDAI-2K score.

Results SLE patients were divided in two groups according disease activity: patients with SLEDAI-2K ≥6 (n:13) had a higher percentage of circulating CD4+T-cells with CD28neg phenotype: median value (25th-75th percentile)=13 (5–19) vs 3 (1–5) % of CD4+ T-cells, p<0.01), as well as of those with an effector memory (37 (29–40) vs 18 (12–27) % of CD4+ T-cells, p<0.01), highly experienced memory phenotype (9 (7–12) vs 1 (1–3) % of CD4+ T-cells, p<0.01), and of B-cells with a transitional phenotype (3 (0.5–5) vs 0.2 (0–0.4) % of CD19+ cells, p=0.02), in comparison with patients with low disease activity (n:38).

After 6 months of treatment with belimumab, no significant variation in the T-cell subset was observed, but there was a reduction in the number of circulating naïve B-cells (from 49 (30–71) to 21 (11–36) % of CD19+ cells; p<0.01). Among these patients, the proportion of transitional B-cells, was raised (as compared with normal controls) at baseline in 3/11 patients with SLEDAI-2K ≥6, and 0/7 with low disease activity. After 6 month of therapy, their number normalized in 2 of these 3 patients.

Conclusions CD4+ T-cells subpopulations displaying phenotype characteristics of effector lymphocytes, and transitional B-cells are expanded in peripheral blood of patients with active SLE. Therapy with belimumab may inhibit the production of transitional and naïve B-cells.


  1. Strioga M, et al. Immunology 2011.

  2. Ugarte-Gil M, et al. Lupus 2016.

  3. Jacobi AM, et al. Arthritis Rheum 2008.


Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.